Intestinal damage occurs during acute and chronic HIV infection despite suppressive antiretroviral therapy and is posited to be one of the drivers of residual chronic immune activation and inflammation. Our study aims to assess intestinal damage as measured by serum intestinal fatty acid binding protein (I-FABP) to further elucidate its role on body composition in individuals living with HIV.
Observational cross-sectional analysis of 154 men and women living with chronic HIV (66% men, mean age 47±7 years) and 69 HIV negative controls (59% men, age 46±7 years) with similar BMI and cardiovascular risk factors was performed. Serum I-FABP was measured by ELISA. Markers of inflammation and immune activation as well as lipopolysaccharides (LPS) were measured. Anthropometric measurements, DXA and single slice abdominal CT were obtained to assess body composition and visceral and subcutaneous adipose tissue areas.
Serum I-FABP was higher in the HIV-infected group (3373 pg/ml [1976-4527]) in comparison to the non-HIV control group (1633 pg/ml [1149-2127]) (p<0.0001). Serum I-FABP was negatively associated with BMI (ρ=-0.36, p=<0.0001), truncal fat (ρ=-0.47, p<0.0001), arm fat (ρ=-0.48, p<0.0001), SAT (ρ=-0.24, p=0.003), and VAT (ρ=-0.28, p=0.0005), and positively associated with adiponectin (ρ=0.20, p=0.04) in the HIV-infected group. These relationships were not seen in the HIV-negative control group. Serum I-FABP was positively related to MCP-1 (ρ=0.19, p=0.005), CXCL10 (ρ=0.30, p=0.008), sCD163 (ρ=0.26, p=<0.0001), LPS (ρ=0.16, p=0.03) and to the percent of HLA-DR+CD38+ CD4+ T cells (ρ=0.26, p=0.02) among all participants.
People living with chronic HIV have significantly higher I-FABP than HIV negative controls. I-FABP was also positively related to markers of microbial translocation, monocyte activation and T-cell activation markers. Interestingly, I-FABP was strongly negatively correlated with BMI and adiposity in subcutaneous and visceral fat compartments among people living with HIV, suggesting that intestinal damage from HIV infection may lead to impaired intestinal absorption and fat loss. Future studies to investigate the role of I-FABP or intestinal damage on fat metabolism are needed to elucidate mechanisms of this observed relationship in people living with HIV.